News stories about Trinity Biotech (NASDAQ:TRIB) have trended positive recently, according to Accern Sentiment. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Trinity Biotech earned a news impact score of 0.36 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.9855874345972 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Separately, Zacks Investment Research lowered Trinity Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, September 20th.
Trinity Biotech (TRIB) opened at $5.33 on Friday. The firm has a market capitalization of $128.14, a PE ratio of -1.47 and a beta of 1.41. The company has a current ratio of 5.16, a quick ratio of 3.77 and a debt-to-equity ratio of 0.90. Trinity Biotech has a 12-month low of $4.22 and a 12-month high of $7.20.
WARNING: This news story was first reported by Markets Daily and is the property of of Markets Daily. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.themarketsdaily.com/2018/01/14/trinity-biotech-trib-given-news-sentiment-score-of-0-36.html.
Trinity Biotech Company Profile
Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine.
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.